RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aptose Biosciences - Stock

Aptose Biosciences P/S 2024

Aptose Biosciences P/S

0

Ticker

APS.TO

ISIN

CA03835T2002

WKN

A12C5N

As of Jun 29, 2024, Aptose Biosciences's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Aptose Biosciences P/S history

Aptose Biosciences Aktienanalyse

What does Aptose Biosciences do?

The company Aptose Biosciences was founded in 1986 and is based in Toronto, Canada. It specializes in the discovery and development of drugs for the treatment of cancer and other serious diseases. History: Aptose Biosciences was originally known as Lorus Therapeutics, specializing in the development of antibodies and peptides. However, in 2007, the company changed its name to Aptose Biosciences and focused on cancer drugs. In 2011, Aptose obtained the license for CG'806, a promising cancer therapy that was later introduced into clinical development in 2017. Business model: Aptose Biosciences' business model is based on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company works closely with leading scientists and researchers to identify and develop new and innovative therapies that have the potential to improve patients' lives. Aptose Biosciences also collaborates with pharmaceutical companies worldwide to advance the development and commercialization of its products. Divisions: Aptose Biosciences focuses on two main areas: the discovery and development of cancer therapies and the discovery of biomarkers that can be used in the diagnosis and treatment of cancer. The cancer therapy division of Aptose focuses on the development of drugs that can target the causes of cancer. The company utilizes innovative technologies to identify and develop new and promising drug candidates that have the potential to improve the lives of patients with various types of cancer. The biomarker division of Aptose focuses on the discovery of biomarkers that can be useful in the diagnosis and treatment of cancer. The company collaborates closely with other companies and research institutions to identify and validate new biomarkers that can contribute to the improvement of cancer diagnosis and treatment. Products: Aptose Biosciences currently offers several cancer drugs that are in different stages of clinical development. The most promising product of Aptose Biosciences is CG'806, which is currently in phase 1 clinical development. CG'806 is a first-in-class cancer drug that has the potential to combat multiple types of cancer. Other products of Aptose Biosciences include APTO-253, which is used for the treatment of AML (acute myeloid leukemia), and APTO-267, which is used for the treatment of CLL (chronic lymphocytic leukemia). Additionally, Aptose Biosciences is working on the development of other cancer therapies that are in various stages of development. Conclusion: Aptose Biosciences is a leading biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company has several promising cancer therapies in different stages of clinical development, as well as a promising biomarker division specializing in cancer diagnosis and treatment. With a strong focus on innovation and collaboration, Aptose Biosciences remains an important player in cancer research and therapy. Aptose Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Aptose Biosciences's P/S Ratio

Aptose Biosciences's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Aptose Biosciences's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Aptose Biosciences's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Aptose Biosciences’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Aptose Biosciences Stock

What is the price-to-earnings ratio of Aptose Biosciences?

The price-earnings ratio of Aptose Biosciences is currently 0.

How has the price-earnings ratio of Aptose Biosciences changed compared to last year?

The price-to-earnings ratio of Aptose Biosciences has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Aptose Biosciences high compared to other companies?

Yes, the price-to-earnings ratio of Aptose Biosciences is high compared to other companies.

How does an increase in the price-earnings ratio of Aptose Biosciences affect the company?

An increase in the price-earnings ratio of Aptose Biosciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Aptose Biosciences affect the company?

A decrease in the price-earnings ratio of Aptose Biosciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Aptose Biosciences?

Some factors that influence the price-earnings ratio of Aptose Biosciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Aptose Biosciences pay?

Over the past 12 months, Aptose Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aptose Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Aptose Biosciences?

The current dividend yield of Aptose Biosciences is .

When does Aptose Biosciences pay dividends?

Aptose Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aptose Biosciences?

Aptose Biosciences paid dividends every year for the past 0 years.

What is the dividend of Aptose Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aptose Biosciences located?

Aptose Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aptose Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aptose Biosciences from 6/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/29/2024.

When did Aptose Biosciences pay the last dividend?

The last dividend was paid out on 6/29/2024.

What was the dividend of Aptose Biosciences in the year 2023?

In the year 2023, Aptose Biosciences distributed 0 USD as dividends.

In which currency does Aptose Biosciences pay out the dividend?

The dividends of Aptose Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aptose Biosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aptose Biosciences

Our stock analysis for Aptose Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aptose Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.